Daiken Medical Co., Ltd.
TTSE:7775425.00
JPY
-7.00
(-1.62%)
ISIN
JP3482500000
Return %
Stock
S&P 500
1Y
-5.97
14.20
3Y
-19.66
81.12
5Y
-26.47
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Keiichi Yamada
- Full Time Employees
- 185
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- 2-6-2, Ayumino Osaka OS Japan 594-1157
- IPO Date
- Mar 16, 2009
- Website
- daiken-iki.co.jp
- Similar Companies
- Business
- Daiken Medical Co., Ltd. is a Japanese medical device manufacturer specializing in the development, manufacturing, and sale of innovative medical equipment primarily focused on preventing hospital-acquired infections and managing postoperative pain. The company's core product portfolio includes suction devices; balloon type and syringe type disposable infusion pumps; endobronchial blocker tubes; wet disinfectant mats; and its proprietary COOPDECH branded products such as COOPDECH Amy PCA for postoperative pain management and COOPDECH FitFix for infection prevention. Founded in 1968 and headquartered in Nishinomiya, Japan, Daiken Medical operates mainly within the domestic Japanese market while leveraging cutting-edge technology and direct hospital relationships to drive product development and distribution. In the most recent period, Daiken Medical has demonstrated steady sales growth, notably with strong performance of COOPDECH Amy PCA and its flagship FitFix product during the first half of the fiscal year 2026. The company has managed to maintain sales growth despite a decline in earnings driven by rising material costs and increased research and development expenses, which are expected to continue into the second half of the fiscal year. Daiken Medical is actively increasing its R&D investment, targeting expansions into areas such as internal medicine and surgery to broaden its medical device offerings. The company continues to place emphasis on innovation and proprietary technology advancements to maintain its competitive edge in the medical devices sector. Daiken Medical is publicly traded on the Tokyo Stock Exchange under the ticker 7775.T. Its recent strategic focus includes reinforcing its product pipeline with next-generation infusion pumps and pain management systems, supporting home healthcare applications, and sustaining its leadership in infection control solutions. The company maintains a vertically integrated business model encompassing research, manufacturing, and direct sales to hospitals, which supports tight control over quality and market responsiveness within Japan. This approach, along with ongoing partnerships and targeted R&D, positions Daiken Medical as a key player in the Japanese medical device industry.